改善急性冠脉综合征患者的脂质管理:ACS脂质EuroPath工具

4区 医学 Q1 Medicine Atherosclerosis. Supplements Pub Date : 2020-12-01 DOI:10.1016/j.atherosclerosissup.2021.01.011
Alessandro Sionis , Alberico L. Catapano , Gaetano M. De Ferrari , Dariusz Dudek , J. Wouter Jukema , Ulf Landmesser , Angela Pirillo , François Schiele , Azfar Zaman , Jose L. Zamorano
{"title":"改善急性冠脉综合征患者的脂质管理:ACS脂质EuroPath工具","authors":"Alessandro Sionis ,&nbsp;Alberico L. Catapano ,&nbsp;Gaetano M. De Ferrari ,&nbsp;Dariusz Dudek ,&nbsp;J. Wouter Jukema ,&nbsp;Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;François Schiele ,&nbsp;Azfar Zaman ,&nbsp;Jose L. Zamorano","doi":"10.1016/j.atherosclerosissup.2021.01.011","DOIUrl":null,"url":null,"abstract":"<div><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients.</p><p>Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e65-e71"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.011","citationCount":"0","resultStr":"{\"title\":\"Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool\",\"authors\":\"Alessandro Sionis ,&nbsp;Alberico L. Catapano ,&nbsp;Gaetano M. De Ferrari ,&nbsp;Dariusz Dudek ,&nbsp;J. Wouter Jukema ,&nbsp;Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;François Schiele ,&nbsp;Azfar Zaman ,&nbsp;Jose L. Zamorano\",\"doi\":\"10.1016/j.atherosclerosissup.2021.01.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients.</p><p>Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.</p></div>\",\"PeriodicalId\":8592,\"journal\":{\"name\":\"Atherosclerosis. Supplements\",\"volume\":\"42 \",\"pages\":\"Pages e65-e71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.011\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis. Supplements\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567568821000131\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis. Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567568821000131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

急性冠脉综合征(ACS)后患者复发和死亡的风险非常高,尽管有有效的药物治疗方法。2018年,与555名欧洲心脏病专家合作进行的ACS欧洲路径调查发现,ACS后患者的LDL-C管理不理想。基于这些前提,ACS EuroPath II项目开发了一种自我评估工具,以改善这些高危患者的脂质管理,并考虑到新的2019年ESC/EAS指南。该工具分为3个部分构建。首先是一份调查问卷,评估从急性期到12个月随访期间的脂质管理实践。本节涵盖的主要主题涉及1)急性期(住院期间ACS患者的脂质管理;2)出院(出院时血脂管理,重点是随访计划);3)随访(首次及后续随访时的血脂管理);4) acs后患者明确脂质管理护理的转诊途径;5)评价6个月至1年的目标实现情况及关键影响。第二部分是一份简短的报告,将结果与其他欧盟临床实践和欧洲指南进行对比。最后一部分允许医生评估和考虑在领先的欧洲中心成功开发的一种或多种策略的实施,以优化他们自己的临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool

Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients.

Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Atherosclerosis. Supplements
Atherosclerosis. Supplements 医学-外周血管病
CiteScore
4.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations.
期刊最新文献
Historical and pathological overview of Castleman disease. Clinical outcomes in pediatric hydrocephalus patients treated with endoscopic third ventriculostomy and choroid plexus cauterization: a systematic review and meta-analysis. Smoker characteristics and trends in tobacco smoking in Rakai, Uganda, 2010-2018. A Potential Nutritional Indicator Predictable for Stroke-Related Sarcopenia. CORRIGENDUM: Outcomes of Dilated Cardiomyopathy in Japanese Children - A Retrospective Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1